Clinical Trial Update: IGIV Study for Chronic ITP Patients Ages 3-70 [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating intravenous immunoglobulin for chronic immune thrombocytopenia in patients aged 3-70 has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Intravenous immunoglobulin (IGIV) (intravenous immunoglobulin)

Snippet

Sponsor: Grifols Biologicals, LLC | Conditions: Idiopathic Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED | Results posted: 2017-05-05